Post by Deleted on Jan 5, 2019 9:03:18 GMT -5
Those incentive trips are put together well in advance of when they take place. No idea if there really was a trip to Hawaii but if there was, it was booked at least 12 months prior. In Pharma, the next years incentive trip is announced during the annual meeting. To cancel the trip or not have execs go when they are expected to do so sends a message to the troops so cancelling the execs attendance saves money but also telegraphs bad things to the reps. As far as the recent raise, not happy about how SP responded. Never met Binder, seems bright but no idea as to how much capital markets savvy / experience he has. Know a guy who became a CFO of large established publicly traded company. Big 4 partner, seasoned, bright and experienced. Said he was blown away first year of job by how much he did not know about dealing with capital markets, hedge funds etc. As far as warrants holding down SP, true and Mannkind has had a lot of headwinds some normal and many not...
We have a pretty good idea what 2019 strategy is for Afrezza in the US as well as plans for TS with four focus molecules. Bottom line is for shorts to go away and warrants to become a non-suppressive drag on share price, Afrezza sales in the US need to increase a lot in 2019 ($50mm net to MNKD) and there needs to be an additional TS deal or two that brings in $40mm or so each. Do these things, SP and warrants will take care of themselves. Mike has enough experience with Mannkind that a lot of kinks have been worked through. More challenges no doubt there is more focus on Afrezza, bigger ad spends, cash program, 2 in 1 Rx card that gets patient onto Afrezza without PA issues (PA with this card gets handled after the purchase in manner transparent to patient) and sales territories that will be more efficient. The experience dealing with United for the TS deal will help Mannkind do similar deals in the future with the knowledge and experience gained from negotiating with United. Short term, look at Rx data every Friday. It's the tell for a big part of 2019 plans. Mannkind will succeed or fail based on 2019 results. More compelling data about Afrezza will help but if 2019 is a bust, things get pushed back another 12-18 months and time is moving on and its no longer our friend.
We have a pretty good idea what 2019 strategy is for Afrezza in the US as well as plans for TS with four focus molecules. Bottom line is for shorts to go away and warrants to become a non-suppressive drag on share price, Afrezza sales in the US need to increase a lot in 2019 ($50mm net to MNKD) and there needs to be an additional TS deal or two that brings in $40mm or so each. Do these things, SP and warrants will take care of themselves. Mike has enough experience with Mannkind that a lot of kinks have been worked through. More challenges no doubt there is more focus on Afrezza, bigger ad spends, cash program, 2 in 1 Rx card that gets patient onto Afrezza without PA issues (PA with this card gets handled after the purchase in manner transparent to patient) and sales territories that will be more efficient. The experience dealing with United for the TS deal will help Mannkind do similar deals in the future with the knowledge and experience gained from negotiating with United. Short term, look at Rx data every Friday. It's the tell for a big part of 2019 plans. Mannkind will succeed or fail based on 2019 results. More compelling data about Afrezza will help but if 2019 is a bust, things get pushed back another 12-18 months and time is moving on and its no longer our friend.